CAR-T cell therapies are a promising approach for treating solid tumors. But identifying appropriate T-Cell receptor (TCR) domains that exclusively target tumor antigens remains a challenge. Toxicity, tumor activation, and tumor persistence are significant challenges to using CAR-T cell therapies for solid tumors.In this webinar, Twist Bioscience’s CSO, Aaron Sato, will present several proof-of-concept studies showing how these technologies can be utilized for cell therapies. Aaron will also be joined by Justin Farlow, CTO of Serotiny, who will tell the story of how Twist’s Combinatorial Assembly Libraries helped his company design and evaluate thousands of CARs, each with novel intracellular signaling architectures. By using these libraries, Serotiny rapidly selected multiple novel CAR designs to enhance the therapeutic performance of primary T-cells.

Twist synthetic DNA technologies have enabled the development of precision antibody libraries designed to bind to G protein-coupled receptors (GPCRs). We have employed high throughput binding and functional assays to discover antibodies with agonist and antagonist profiles. This parallel functional screening was successfully employed for discovery of novel therapeutic antibody ligands for three GPCRs (called GLP1R, APJR and C5AR1). Twist synthetic DNA technologies allow for the design of novel antibody-based GPCR ligands with profiles for clinical therapeutic development.    

Bioscience provides a complete on-demand Gene to Antibody high-throughput production service to help centralize and streamline antibody production for downstream characterization. Our platform fits well in your discovery process in times of capacity constraint or times of added support for antibody production. In addition to production, we also offer a set of characterization services that can help alleviate the bottleneck of initial downstream characterization that can often burden the lab.